8-K: CooperCompanies Reports Record Revenue and Earnings for Fiscal Year 2024

CooperCompanies announced record consolidated revenues, including record revenues for both CooperVision and CooperSurgical, along with record non-GAAP earnings per share for fiscal year 2024.

Summary

• CooperCompanies reported a strong fiscal year 2024, achieving record consolidated revenues of $3.9 billion, an 8% increase year-over-year, with the same 8% growth organically.
• The company's fourth-quarter revenue reached $1,018.4 million, a 10% increase, or 7% organically.
• GAAP diluted earnings per share (EPS) for the fourth quarter was $0.58, a 38% increase, and for the full year was $1.96, a 33% increase.
• Non-GAAP diluted EPS for the fourth quarter was $1.04, a 19% increase, and for the full year was $3.69, a 15% increase.
• CooperVision (CVI) revenue for the fourth quarter was $676.4 million, up 9%, or 8% organically, while CooperSurgical (CSI) revenue was $342.0 million, up 12%, or 5% organically.
• The company's gross margin for the fourth quarter was 67%, up from 65% last year, and operating margin was 19%, up from 15% last year.
• Free cash flow for the fourth quarter was $128.2 million, and for the full year was $288.1 million.
• Fiscal year 2025 revenue is projected to be between $4.08 billion and $4.158 billion, with organic growth of 6% to 8%, and non-GAAP diluted EPS is projected to be between $3.92 and $4.02.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to record revenues, strong earnings growth, and positive future guidance. The company's performance is clearly exceeding expectations, and management's comments are optimistic.

Positives

• The company achieved record consolidated revenues, including record revenues for both CooperVision and CooperSurgical.
• Both GAAP and non-GAAP diluted EPS showed significant year-over-year growth.
• Gross and operating margins improved compared to the previous year.
• The company generated strong free cash flow.
• The company provided positive financial guidance for fiscal year 2025, projecting continued revenue and earnings growth.

Negatives

• Interest expense increased slightly in the fourth quarter, from $26.3 million to $27.0 million.
• Capital expenditures were significant, at $139.9 million for the fourth quarter and $421.2 million for the full year.

Risks

• The company's future performance is subject to various risks, including adverse changes in global economic conditions, international conflicts, and foreign currency fluctuations.
• The company faces risks related to acquisitions, including integration challenges and potential liabilities.
• There are risks associated with compliance with U.S. and foreign laws and healthcare regulations, including data privacy and security.
• The company's operations could be disrupted by cybersecurity attacks, supply chain issues, or other unforeseen events.
• The company faces competition from other medical device companies and is subject to regulatory approvals and market acceptance of its products.

Future Outlook

The company initiated its fiscal year 2025 financial guidance, projecting total revenue between $4.08 billion and $4.158 billion, with organic growth of 6% to 8%, and non-GAAP diluted EPS between $3.92 and $4.02.

Management Comments

• Al White, Cooper's President and CEO, stated that fiscal 2024 was a great year for Cooper, having achieved record consolidated revenues, including record CooperVision revenues, record CooperSurgical revenues, and record non-GAAP EPS.
• He also mentioned that they look forward to continued success in fiscal 2025 and thanked all employees for driving these results.

Industry Context

This announcement reflects a positive trend in the medical device industry, with CooperCompanies demonstrating strong growth in both its contact lens and surgical segments. The company's performance is indicative of the increasing demand for medical devices and healthcare products globally.

Comparison to Industry Standards

• CooperCompanies' 8% organic revenue growth for the full year is strong compared to industry peers such as Alcon (ALC) and Bausch + Lomb (BLCO), which have reported mid-single-digit growth in recent periods.
• The company's non-GAAP EPS growth of 15% for the full year is also competitive, exceeding the average growth rate of many medical device companies.
• The 67% gross margin is in line with industry leaders, indicating efficient operations and pricing strategies.
• The projected 6% to 8% organic revenue growth for fiscal year 2025 suggests continued confidence in the company's market position and product offerings.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive future guidance.
• Employees are recognized for their contributions to the company's success.
• Customers will benefit from the company's continued investment in product development and innovation.
• Suppliers will likely see continued demand for their products and services.
• Creditors will be reassured by the company's strong financial position and cash flow.

Next Steps

• The company will host an audio webcast to discuss its fourth quarter results and current corporate developments.
• The company will focus on achieving its fiscal year 2025 financial guidance.

Key Dates

Keywords

medical devices, contact lenses, fertility, women's health, revenue, earnings per share, EPS, financial results, CooperVision, CooperSurgical, organic growth, gross margin, operating margin, free cash flow